Use in Immunocytochemistry/immunofluorescence reported in scientific literature (PMID 24480790). Use in Immunohistochemistry-Frozen reported in scientific literature (PMID 28285877).
46 kDa. Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Mouse reactivity reported in scientific literature (PMID: 16807363). Human reactivity reported in scientific literature (PMID: 24480790). Turkey reactivity reported in scientific literature (PMID: 27055929). Zebrafish reactivity reported in scientific literature (PMID: 28285877).
Packaging, Storage & Formulations
Store at -20C. Avoid freeze-thaw cycles.
Neat whole antisera
Alternate Names for GABA-A R gamma 2 Antibody
GABA A R gamma 2
GABA(A) receptor subunit gamma-2
GABAAR gamma 2
gamma-aminobutyric acid (GABA) A receptor, gamma 2
gamma-aminobutyric acid receptor subunit gamma-2
Gamma-aminobutyric acid (GABA) is the primary inhibitory neurotransmitter in the central nervous system, causing a hyperpolarization of the membrane through the opening of a Cl(-) channel associated with the GABAA receptor (GABAA-R) subtype. GABAA-Rs are important therapeutic targets for a range of sedative, anxiolytic, and hypnotic agents and are implicated in several diseases including epilepsy, anxiety, depression, and substance abuse. The GABAA-R is a multimeric subunit complex. To date six alphas, four betas and four gammas, plus alternative splicing variants of some of these subunits, have been identified (Olsen and Tobin, 1990; Whiting et al., 1999; Ogris et al., 2004). Injection in oocytes or mammalian cell lines of cRNA coding for alpha- and beta-subunits results in the expression of functional GABAA-Rs sensitive to GABA. However, co-expression of a gamma-subunit is required for benzodiazepine modulation. The various effects of the benzodiazepines in brain may also be mediated via different alpha-subunits of the receptor (McKernan et al., 2000; Mehta and Ticku, 1998; Ogris et al., 2004; Poltl et al., 2003). Lastly, phosphorylation of beta-subunits of the receptor has been shown to modulate GABAA-R function (Brandon et al., 2003).
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
FAQs for GABA-A R gamma 2 Antibody (NB300-151). (Showing 1 - 2 of 2 FAQs).
I am looking for a "Primary antibody for GABAa receptor gamma 2" raised from antigen whose aa sequence is between exon 5-10. The application will be for "Immunohistochemistry". I would like to know if you have a product to match it?
NB300-190 is direceted against GABA A receptor gamma 2, is suitable for use in IHC and uses a fusion protein from the cytoplasmic loop of the gamma 2 subunit as an antigen, so this should suit your needs.
Are there neutralizing peptides for this antibody?
There is no neutralizing peptide available for this antibody.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our GABA-A R gamma 2 Antibody and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.